Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

키워드

참고문헌 (49)

1. Younossi Z, "Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 69, pp.2672~2682 (2019)
2. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
3. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
4. Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
5. Noureddin M, "NASH leading cause of liver transplant in women : updated analysis of indications for liver transplant and ethnic and gender variances", Am J Gastroenterol, 113, pp.1649~1659 (2018)
6. Anstee QM, "From NASH to HCC : current concepts and future challenges", Nat Rev Gastroenterol Hepatol, 16, pp.411~428 (2019)
7. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
8. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378 (2015)
9. Theresa J. Hydes, "Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH", Clinical and Molecular Hepatology, 26(4), pp.383~400 (2020), 대한간학회[DOI]
10. Wong VW, "Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease", J Hepatol, 69, pp.1349~1356 (2018)
11. Franz MJ, "Weight-loss outcomes : a systematic review and metaanalysis of weight-loss clinical trials with a minimum 1-year follow-up", J Am Diet Assoc, 107, pp.1755~1767 (2007)
12. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
13. Patel Chavez C, "The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD", J Clin Endocrinol Metab, 107, pp.29~38 (2022)
14. Arroyave-Ospina JC, "Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease:implications for prevention and therapy", Antioxidants(Basel), 10, pp.174~ (2021)
15. Jiang Q, "Natural forms of vitamin E : metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy", Free Radic Biol Med, 72, pp.76~90 (2014)
16. Bril F, "Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes : a randomized controlled trial", Diabetes Care, 42, pp.1481~1488 (2019)
17. Cusi K, "American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings : co-sponsored by the American Association for the Study of Liver Diseases(AASLD)", Endocr Pract, 28, pp.528~562 (2022)
18. Klein EA, "Vitamin E and the risk of prostate cancer : the Selenium and Vitamin E Cancer Prevention Trial(SELECT)", JAMA, 306, pp.1549~1556 (2011)
19. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
20. Aithal GP, "Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis", Gastroenterology, 135, pp.1176~1184 (2008)
21. Cusi K, "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus : a randomized trial", Ann Intern Med, 165, pp.305~315 (2016)
22. Musso G, "Thiazolidinediones and Advanced liver fibrosis in nonalcoholic steatohepatitis : a meta-analysis", JAMA Intern Med, 177, pp.633~640 (2017)
23. Kyung-Soo Kim, "Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 26(4), pp.430~443 (2020), 대한간학회[DOI]
24. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
25. Day JW, "A new glucagon and GLP-1 co-agonist eliminates obesity in rodents", Nat Chem Biol, 5, pp.749~757 (2009)
26. Robertson D, "PROXYMO demonstrates safety and efficacy of cotadutide, a novel incretin co-agonist in biopsy-proven non-cirrhotic NASH with fibrosis. Oral abstract", Hepatology, 74, pp.1383A~ (2021)
27. Modica S, "Deciphering the nuclear bile acid receptor FXR paradigm", Nucl Recept Signal, 8, pp.e005~ (2010)
28. Claudel T, "The Farnesoid X receptor : a molecular link between bile acid and lipid and glucose metabolism", Arterioscler Thromb Vasc Biol, 25, pp.2020~2030 (2005)
29. Fiorucci S, "The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis", Gastroenterology, 127, pp.1497~1512 (2004)
30. Wang YD, "Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response", Hepatology, 48, pp.1632~1643 (2008)
31. Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
32. "Intercept pharmaceuticals announces REVERSE phase 3 study of obeticholic acid (OCA) in compensated cirrhosis due to NASH did not meet its primary endpoint" (2006)[URL]
33. Francque S, "Nonalcoholic steatohepatitis : the role of peroxisome proliferator-activated receptors", Nat Rev Gastroenterol Hepatol, 18, pp.24~39 (2021)
34. Wettstein G, "The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis", Hepatol Commun, 1, pp.524~537 (2017)
35. Lefere S, "Differential effects of selective-and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages", J Hepatol, 73, pp.757~770 (2020)
36. Francque SM, "A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH", N Engl J Med, 385, pp.1547~1558 (2021)
37. "Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH) (RESOLVE-IT)"[URL]
38. Reinehr T, "Obesity and thyroid function", Mol Cell Endocrinol, 316, pp.165~171 (2010)
39. Sinha RA, "Nonalcoholic fatty liver disease and hypercholesterolemia : roles of thyroid hormones, metabolites, and agonists", Thyroid, 29, pp.1173~1191 (2019)
40. Harrison SA, "Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
41. Harrison S, "Primary data analyses of MAESTRO-NAFLD-1 a 52 week doubleblind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD", J Hepatol, 77, pp.S14~ (2022)
42. Ichijo H, "Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK", JNK and p38 signaling pathways, 1997, pp.275, 90~94
43. Naoshi Odagiri, "Anti-fibrotic treatments for chronic liver diseases: The present and the future", Clinical and Molecular Hepatology, 27(3), pp.413~424 (2021), 대한간학회[DOI]
44. Loomba R, "The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial", Hepatology, 67, pp.549~559 (2018)
45. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
46. Loomba R, "Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH", Hepatology, 73, pp.625~643 (2021)
47. Ajmera VH, "MRI assessment of treatment response in HIV-associated NAFLD : a randomized trial of a Stearoyl-Coenzyme-A-Desaturase-1 inhibitor(ARRIVE trial)", Hepatology, 70, pp.1531~1545 (2019)
48. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
49. Attia SL, "Evolving role for pharmacotherapy in NAFLD", NASH, 2021, pp.14, 11~19

관련 논문AI추천